Effect of calcium on the growth inhibition induced by ibandronate in MDA-MB-231 and MCF-7 cells

Cells were treated for 72 hours with 30 μmol/l ibandronate (open circles) in the presence of increasing concentrations of calcium (0.6 to 2.0 mmol/l; filled circles, no ibandronate). Cell culture densities were determined by crystal violet staining assay. Data are expressed as percentages (mean ± standard deviation) of control values, which refer to cultures in presence of 0.6 mmol/l calcium and without ibandronate. Mean of results pooled from three experiments (= 18). *< 0.01 versus no ibandronate, analysis of variance, Tukey test.<p><b>Copyright information:</b></p><p>Taken from "Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells"</p><p>http://breast-cancer-research.com/content/10/1/R4</p><p>Breast Cancer Research : BCR 2008;10(1):R4-R4.</p><p>Published online 11 Jan 2008</p><p>PMCID:PMC2374955.</p><p></p

Pulse exposures of cancer cells to ibandronate in presence of low or high calcium concentrations

MDA-MB-231 and MCF-7 cells were incubated for 1, 6, or 72 hours with ibandronate (1 to 1,000 μmol/l) in culture medium containing 0.6 mmol/l calcium (filled circles) or 1.6 mmol/l calcium (open circles). Cell culture densities were evaluated at 72 hours by crystal violet staining assay. Data are presented as percentages (mean ± standard deviation) of control values, which refer to cultures with 0.6 mmol/l calcium and without ibandronate. Mean of results pooled from three experiments (= 18).<p><b>Copyright information:</b></p><p>Taken from "Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells"</p><p>http://breast-cancer-research.com/content/10/1/R4</p><p>Breast Cancer Research : BCR 2008;10(1):R4-R4.</p><p>Published online 11 Jan 2008</p><p>PMCID:PMC2374955.</p><p></p

Effect of calcium on ibandronate-induced inhibition of Rap1A prenylation in MDA-MB-231 and MCF-7 cells

Cells were incubated for 24 hours with increasing concentrations of ibandronate (1 to 1,000 μmol/l) in culture medium containing 0.6 or 2.0 mmol/l calcium, lysed and subjected to Western blot analysis. Equal amounts of proteins (25 μg) were subjected to 12% SDS-PAGE and electrotransferred onto nitrocellulose membranes. Immunodetection was performed with a goat polyclonal anti-human antibody raised against the unprenylated form of Rap1A. Total Rap1 protein (input) was evaluated in parallel using a rabbit polyclonal anti-human Rap1 antibody. Representative data from two separate experiments.<p><b>Copyright information:</b></p><p>Taken from "Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells"</p><p>http://breast-cancer-research.com/content/10/1/R4</p><p>Breast Cancer Research : BCR 2008;10(1):R4-R4.</p><p>Published online 11 Jan 2008</p><p>PMCID:PMC2374955.</p><p></p

Effect of calcium on cell apoptosis induced by bisphosphonates in MDA-MB-231 and MCF-7 cells

Cells were incubated for 72 hours with 30 μmol/l ibandronate (Iban) or zoledronic acid (Zole) in culture medium containing 0.6 or 1.6 mmol/l calcium. Apoptotic cell death was assessed by annexin V-phycoerythrin (PE) and 7-amino-actinomycin (7-AAD) double staining. Data are presented as percentages (mean ± standard deviation) of annexin V-PE-positive (AN) and 7-AAD-negative cells. Mean of results pooled from two experiments (= 4). *< 0.01 versus 0.6 mmol/l calcium, analysis of variance, Tukey test.<p><b>Copyright information:</b></p><p>Taken from "Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells"</p><p>http://breast-cancer-research.com/content/10/1/R4</p><p>Breast Cancer Research : BCR 2008;10(1):R4-R4.</p><p>Published online 11 Jan 2008</p><p>PMCID:PMC2374955.</p><p></p

Effects of CaR agonist and antagonist on growth inhibition caused by ibandronate in cancer cells

MDA-MB-231 and MCF-7 cells were incubated for 72 hours with 30 μmol/l ibandronate (Iban) and/or calcium-sensing receptor (CaR) agonist in culture medium containing 0.6 mmol/l calcium, or with 30 μmol/l ibandronate and/or CaR antagonist in culture medium containing 1.6 mmol/l calcium. Cell culture densities were evaluated by crystal violet staining assay. Data are presented as percentages (mean ± standard deviation) of control values, which refer to culture with 0.6 mmol/l calcium and without drugs. Mean of results pooled from two experiments (= 12). *< 0.01 versus control, analysis of variance, Dunnett test.<p><b>Copyright information:</b></p><p>Taken from "Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells"</p><p>http://breast-cancer-research.com/content/10/1/R4</p><p>Breast Cancer Research : BCR 2008;10(1):R4-R4.</p><p>Published online 11 Jan 2008</p><p>PMCID:PMC2374955.</p><p></p

Comparative study of calcium effect on zoledronic acid or paclitaxel, and magnesium effect on ibandronate

Cells were exposed for 72 hours to increasing concentrations of zoledronic acid (1 to 1,000 μmol/l) or to increasing concentrations of paclitaxel (0.1 to 1,000 μmol/l), in culture medium containing 0.6 mmol/l calcium (filled squares) or 1.6 mmol/l calcium (open squares), or to 30 μmol/l ibandronate (open circles) in the presence of increasing magnesium concentrations (0.4 to 1.8 mmol/l; filled circles, no ibandronate). Cell culture densities were measured by crystal violet staining assay. Data are presented as percentages (mean ± standard deviation) of control values, which refer to culture with 0.6 mmol/l calcium or 0.4 mmol/l magnesium and without drug. Mean of results pooled from two experiments (= 12).<p><b>Copyright information:</b></p><p>Taken from "Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells"</p><p>http://breast-cancer-research.com/content/10/1/R4</p><p>Breast Cancer Research : BCR 2008;10(1):R4-R4.</p><p>Published online 11 Jan 2008</p><p>PMCID:PMC2374955.</p><p></p

Concentration-effect relationships of ibandronate on cancer cell proliferation in hypocalcaemic or hypercalcaemic conditions

MDA-MB-231 and MCF-7 cells were exposed for 72 hours to increasing ibandronate concentrations (1 to 1,000 μmol/l) in culture medium containing 0.6 mmol/l calcium (filled squares) or 1.6 mmol/l calcium (open squares). Cell culture densities were evaluated by crystal violet staining assay. Data are presented as percentages (mean ± standard deviation) of control values, which refer to cultures with 0.6 mmol/l calcium and without ibandronate. Mean of results pooled from three experiments (= 18). *< 0.01 versus 0.6 mmol/l calcium, analysis of variance, Tukey test.<p><b>Copyright information:</b></p><p>Taken from "Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells"</p><p>http://breast-cancer-research.com/content/10/1/R4</p><p>Breast Cancer Research : BCR 2008;10(1):R4-R4.</p><p>Published online 11 Jan 2008</p><p>PMCID:PMC2374955.</p><p></p

Effect of EGTA on growth inhibition induced by ibandronate in presence of high calcium concentration

MDA-MB-231 and MCF-7 cells were treated for 72 hours with 30 μmol/l ibandronate (Iban) alone or with 500 μmol/l ethylene glycol tetra-acetic acid (EGTA) in culture medium containing 1.6 mmol/l calcium. Cell culture densities were determined by crystal violet staining assay. Data are presented as percentages (mean ± standard deviation) of control values, which refer to culture with 1.6 mmol/l calcium and without drugs. Mean of results pooled from two experiments (= 12). *< 0.01 between indicated conditions, analysis of variance; < 0.01 versus control, analysis of variance; Tukey test.<p><b>Copyright information:</b></p><p>Taken from "Extracellular calcium increases bisphosphonate-induced growth inhibition of breast cancer cells"</p><p>http://breast-cancer-research.com/content/10/1/R4</p><p>Breast Cancer Research : BCR 2008;10(1):R4-R4.</p><p>Published online 11 Jan 2008</p><p>PMCID:PMC2374955.</p><p></p

Additional file 1: of Ambulatory Medical Assistance - After Cancer (AMA-AC): A model for an early trajectory survivorship survey of lymphoma patients treated with anthracycline-based chemotherapy

List of medical complications administered by the general practitioner (GP). (DOCX 32 kb